4.7 Article

Cross-variant protection against SARS-CoV-2 infection in hamsters immunized with monovalent and bivalent inactivated vaccines

Journal

INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES
Volume 18, Issue 12, Pages 4781-4791

Publisher

IVYSPRING INT PUBL
DOI: 10.7150/ijbs.72109

Keywords

COVID-19; Inactivated vaccine; Neutralizing antibodies; Immune protection; SARS-CoV-2 variants of concern

Funding

  1. Hong Kong Research Grants Council [C7142-20GF, T11-709/21-N]
  2. National Key R&D Program of China [2021YFC0866100]
  3. Hong Kong Health and Medical Research Fund [COVID190114]
  4. Guangzhou Laboratory [EKPG22-01]
  5. CVVT of Health@InnoHK

Ask authors/readers for more resources

Rapid development and successful use of vaccines against SARS-CoV-2 are crucial in curbing the ongoing pandemic of COVID-19. However, vaccine-evasive variants of concern have emerged, posing new challenges to vaccine design and development. This study found that monovalent and bivalent variant-specific inactivated vaccines provide optimal protection against their respective variants, while also showing some cross-variant protection.
Rapid development and successful use of vaccines against SARS-CoV-2 might hold the key to curb the ongoing pandemic of COVID-19. Emergence of vaccine-evasive SARS-CoV-2 variants of concern (VOCs) has posed a new challenge to vaccine design and development. One urgent need is to determine what types of variant-specific and bivalent vaccines should be developed. Here, we compared homotypic and heterotypic protection against SARS-CoV-2 infection of hamsters with monovalent and bivalent whole-virion inactivated vaccines derived from representative VOCs. In addition to the ancestral SARS-CoV-2 Wuhan strain, Delta (B.1.617.2; delta) and Theta (P.3; theta) variants were used in vaccine preparation. Additional VOCs including Omicron (B.1.1.529) and Alpha (B.1.1.7) variants were employed in the challenge experiment. Consistent with previous findings, Omicron variant exhibited the highest degree of immune evasion, rendering all different forms of inactivated vaccines substantially less efficacious. Notably, monovalent and bivalent Delta variant-specific inactivated vaccines provided optimal protection against challenge with Delta variant. Yet, some cross-variant protection against Omicron and Alpha variants was seen with all monovalent and bivalent inactivated vaccines tested. Taken together, our findings support the notion that an optimal next-generation inactivated vaccine against SARS-CoV-2 should contain the predominant VOC in circulation. Further investigations are underway to test whether a bivalent vaccine for Delta and Omicron variants can serve this purpose.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available